Brendan O'Leary

Brendan received his doctorate in organic chemistry from the Massachusetts Institute of Technology and a BA in chemistry and economics from Middlebury College. 

​

Brendan is also an accomplished scientist with numerous publications, inventions and commercialized products to his credit.

Brendan recently joined the executive team at UMass Medical School. Brendan's task is to engage with key campus stakeholders to diversify and expand business ventures, enlarge commercialization efforts, enhance entrepreneurial activities, and drive new strategic partnerships. This new role also includes oversight of the Office of Technology Management, where Brendan will be responsible for structuring, negotiating and implementing business transactions, as well as for protecting and fully leveraging the institution's intellectual property portfolio. 

​

Previously, Brendan was with the life sciences team at the venture capital firm Prism VentureWorks for over 10 years. At Prism, Brendan focused on companies in the medical device, pharmaceutical, and diagnostic sectors. While there, he evaluated and mentored hundreds of life science companies as well as taking investment positions and board seats at many of those companies, including Alacer Biomedical (acquired by Allergan), Atritech (acquired by Boston Scientific), BioRexis Pharmaceutical (acquired by Pfizer), Proteon Therapeutics, Serica Technologies (acquired by Allergan), and Trius Therapeutics (NASDAQ: TSRX; acquired by Cubist). Brendan continues to be an active angel investor in early-stage life science companies. 

​

Brendan brings deep background in the biotechnology and medical technology, from his numerous senior operating positions at companies such as Meso Scale Discovery, a high throughput drug discovery start-up, and IGEN International, a leading medical diagnostics company (acquired by Roche).

Brendan is a member of Kauffman Fellows Class 8 and served his fellowship under mentor Bob Fleming at Prism Venture Partners in Boston, MA.